Cerapedics Inc.
$1.1M 2,115 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. reported $1,090,100.60 across General Payments, Research, and Ownership to 153 physicians and teaching hospitals across 230 transactions.
- $1.1M Above-median payer
- All-tracks total
- 230 Above-median volume
- Transactions
- 153 Above-median reach
- Recipients
- #603
- of 1,925 companies
X4 Pharmaceuticals, Inc. reported $1,090,100.60 across all CMS Open Payments tracks (General + Research + Ownership) to 153 physicians and teaching hospitals in Program Year 2024 - ranking #603 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $80,863.28, averaging $7.1K per recipient.
How X4 Pharmaceuticals, Inc.'s $1.1M all-tracks total breaks down
X4 Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
27/100
Total payments
F
20/100
Transaction volume
F
12/100
Physician reach
F
11/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer x4-pharmaceuticals-inc X4 Pharmaceuticals, Inc.
$1.1M · #603/1,925 · 0.0% industry · PY2024
- TOT $1.1M
- RANK #603
- SHARE 0.0%
- TXN 230
- RCP 153
- CAT 5
- GEN $80.9K
- TOP1 49.5%
- PY 2024
Volume peers
Nearest volume peer: Cerapedics Inc. ($1.1M)
X4 Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for X4 Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For X4 Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 5 general-payment categories charted below, "Royalty or License" is the largest at $40.0K across 1 transactions, 49.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 5 types of general payments, X4 Pharmaceuticals, Inc.'s largest category was "Royalty or License" at $40.0K - 49.5% of General Payments.
X4 Pharmaceuticals, Inc. reports 5 general-payment categories - the top three are Royalty or License (49.5%), Consulting Fee (38.7%), and Food and Beverage (7.1%). The remaining 2 categories make up 4.7% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How X4 Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $40.0K | 1 | 49.5% |
| Consulting Fee | $31.3K | 12 | 38.7% |
| Food and Beverage | $5.7K | 126 | 7.1% |
| Travel and Lodging | $3.8K | 13 | 4.7% |
| Education | $42.97 | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $67,997.77 (84.1%) of $80,863.28 in this company's General Payments records across 128 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for X4 Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Dana-Farber Cancer Institute
$40,000.00 across 1 reported transactions
- 2
Niraj Patel
$12,479.73 across 10 reported transactions
- 3
Antoine Azar
$5,827.50 across 2 reported transactions
- 4
Nicholas Hartog
$5,220.54 across 4 reported transactions
- 5
Allison Remiker
$4,470.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
X4 Pharmaceuticals, Inc.'s spend rank (#603 of 1,925, top 31% by spend) and concentration rank (#589 of 1,838, top 32% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Medyssey USA, Inc : $307.8K total payments, HHI 2888
- Vaporox, Inc. : $51.8K total payments, HHI 2887
- Alafair Biosciences, Inc. : $231.7K total payments, HHI 2862
- Aesculap AG : $815.8K total payments, HHI 2859
- Biocartis US, Inc : $9.2K total payments, HHI 2857
- US Endoscopy : $971.8K total payments, HHI 2854
- X4 Pharmaceuticals, Inc. (this company) : $80.9K total payments, HHI 2850
- Ultrasight Inc : $162.3K total payments, HHI 2847
- Steris Corporation : $514.3K total payments, HHI 2847
- Richard Wolf Medical Instruments Corp. : $85.7K total payments, HHI 2845
- Analog Devices Inc. : $22.5K total payments, HHI 2816
- Promega Corporation : $17.3K total payments, HHI 2814
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as X4 Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about X4 Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with X4 Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Harrow Eye, LLC
$1.1M 11,566 recipients
Compare payment profiles
CONMED Corporation
$1.1M 3,570 recipients
Compare payment profiles
Kyowa Kirin Co., Ltd
$1.1M 29 recipients
Compare payment profiles
Neuronetics, Inc.
$1.1M 2,122 recipients
Compare payment profiles
Lumenis BE inc
$1.1M 694 recipients
Compare payment profiles
Put this to use
X4 Pharmaceuticals, Inc. ranks #603 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See where X4 Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just X4 Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.